IL-13-expressing ILC2s are often associated with increased MDSC differentiation and pro-tumorigenic functions in bladder cancer [41], prostate cancer and acute promyelocytic leukemia [40]. This evidence concerns the gene IL13 and urinary bladder carcinoma.